このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

(復活)敗血症関連AKI患者におけるアルカリホスファターゼの有効性と安全性を検討する試験

2026年10月26日 更新者:AM-Pharma

SA-AKI患者の治療のための組換えヒトアルカリホスファターゼの有効性と安全性を調査するためのDB、プラセボ対照、2群並列群、第3相RCT

Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis.

The study has three distinct SA-AKI trial populations:

  1. The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
  2. A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and <45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization.
  3. A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI.

In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients.

There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.

調査の概要

状態

終了しました

条件

介入・治療

詳細な説明

Sepsis is the leading cause of acute kidney injury (AKI) and a major cause of death. Patients with SA-AKI have a high mortality and morbidity and are at risk of developing chronic kidney disease. AP is a homodimeric endogenous enzyme present in many cells and organs, e.g., intestines, placenta, liver, bone, kidney, and granulocytes. It exerts detoxifying effects through dephosphorylation of endotoxins; pathogen associated molecular pattern molecules (PAMPS e.g., lipopolysaccharide) and damage-associated molecular pattern molecules (DAMPS e.g., adenosine tri- and di-phosphate). In animal models of sepsis and AKI, administration of AP attenuates the inflammatory response, improves renal function and/or reduces mortality.

AM-Pharma B.V. is developing AP as a novel, recombinant chimeric human AP medicinal product, called recAP, to be used as an intravenous infusion for the treatment of SA-AKI. In the Phase 2 trial STOP-AKI, a survival benefit was observed in the two highest dose groups, 0.8 mg/kg and 1.6 mg/kg groups, compared to the placebo group. There were no safety or tolerability concerns for any of the doses tested (0.4, 0.8 and 1.6 mg/kg). The 1.6 mg/kg recAP dose was selected for this Phase 3 trial based on the significant survival benefit observed. PK/PD simulations also confirmed this dose to have the most pronounced treatment effect.

The primary objective of this Phase 3 trial is to confirm the mortality benefit seen in STOP-AKI by demonstrating a reduction in 28 day all cause mortality in patients with SA-AKI treated with 1.6 mg/kg recAP.

研究の種類

介入

入学 (実際)

676

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Dublin、アイルランド、D08 NHY1
        • St. James's Hospital
      • Dublin、アイルランド、D24NR0A
        • Tallaght University Hospital
      • Dublin、アイルランド、Dublin 4
        • St. Vincent's University Hospital
    • G
      • Galway、G、アイルランド、H91 YR71
        • National University of Ireland, Galway
    • Arizona
      • Tucson、Arizona、アメリカ、85724-5057
        • The University of Arizona Cancer Center
    • California
      • Los Angeles、California、アメリカ、90095-8358
        • Ronald Reagan UCLA Medical Center
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20037-2342
        • The George Washington University Medical Faculty Associates - Anesthesiology
    • Georgia
      • Atlanta、Georgia、アメリカ、30322-1007
        • Emory Clinical Cardiovascular Research Institute
    • Illinois
      • Glenview、Illinois、アメリカ、60026-1301
        • Glenbrook Hospital
      • Highland Park、Illinois、アメリカ、60035
        • NorthShore Medical Group - Bannockburn
    • Kentucky
      • Lexington、Kentucky、アメリカ、40508-3215
        • University of Kentucky College of Medicine (UKCM)
    • Minnesota
      • Saint Paul、Minnesota、アメリカ、55101
        • Regions Hospital
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87131
        • University of New Mexico School of Medicine
    • North Carolina
      • Winston-Salem、North Carolina、アメリカ、27157
        • Wake Forest Baptist Medical Center
    • Ohio
      • Cincinnati、Ohio、アメリカ、45219
        • University of Cincinnati Cancer Institute
      • Columbus、Ohio、アメリカ、43210
        • The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute
    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15213-3108
        • UPMC CancerCenter at Magee - Womens Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15213-3108
        • UPMC Presbyterian
    • Virginia
      • Charlottesville、Virginia、アメリカ、22908-0817
        • University of Virginia Health System
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226-3522
        • Froedtert & the Medical College of Wisconsin Froedtert Hospital
      • Cardiff、イギリス、CF14 4XW
        • University Hospital of Wales
      • Liverpool、イギリス、L7 8XP
        • Royal Liverpool University Hospital
      • London、イギリス、SE1 7EH
        • Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital
      • Plymouth、イギリス、PL6 8DH
        • Plymouth Hospitals NHS Trust - Derriford Hospital
    • LND
      • London、LND、イギリス、NW1 2BU
        • University College London Hospitals NHS Foundation Trust - University College Hospital
      • Amsterdam、オランダ、1081 HV
        • Amsterdam UMC - VUMC
      • Ede、オランダ、6716 RP
        • Ziekenhuis Gelderse Vallei
      • Enschede、オランダ、KZ 7512
        • Medisch Spectrum Twente
      • Heerlen、オランダ、Heerlen
        • Zuyderland Medisch Centrum, Heerlen
      • Nijmegen、オランダ、6532 SZ
        • Canisius-Wilhelmina Ziekenhuis
      • Nijmegen、オランダ、6500 HB
        • Radboud UMC
    • North Brabant
      • 's-Hertogenbosch、North Brabant、オランダ、5223 GZ
        • Jeroen Bosch Ziekenhuis lokatie GZG
      • Bedford Park、オーストラリア、5042
        • Flinders Medical Centre
      • Bendigo、オーストラリア、3550
        • Bendigo Hospital
      • Footscray、オーストラリア、3011
        • Footscray Hospital
      • Melbourne、オーストラリア、3084
        • Austin Hospital
      • New Lambton Heights、オーストラリア、2305
        • John Hunter Hospital
      • Saint Albans、オーストラリア、3021
        • Sunshine Hospital ICU - Western Hospital
      • Southport、オーストラリア、4215
        • Gold Coast University Hospital (GCUH)
      • Graz、オーストリア、8036
        • Medizinische Universitaet Graz - Klinik fuer Innere Medizin
      • Innsbruck、オーストリア、6020
        • Medizinische Universität Innsbruck
      • Innsbruck、オーストリア、6020
        • Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Innere Medizin I
      • Calgary、カナダ、T1Y 6J4
        • Peter Lougheed Centre
      • Calgary、カナダ、T2N 2T9
        • Foothills Medical Centre
      • Calgary、カナダ、T2V 1P9
        • Rockyview General Hospital
      • Calgary、カナダ、T3M 1M4
        • Alberta Health Services - South Health Campus Hospital
      • Ottawa、カナダ、K1H 8L6
        • The Ottawa Hospital - General Campus
      • Ottawa、カナダ、K1Y 4E9
        • The Ottawa Hospital - Civic Campus
      • Québec、カナダ、G1J 1Z4
        • Hôpital de l'Enfant-Jésus
      • Vancouver、カナダ、V6Z 1Y6
        • St. Paul's Hospital
      • Victoria、カナダ、V8R 1J8
        • Royal Jubilee Hospital (RJH)
      • Victoria、カナダ、V8R 1J8
        • Victoria General Hospital (VGH)
      • Badalona、スペイン、8916
        • Hospital Universitari Germans Trias i Pujol
      • Barcelona、スペイン、8035
        • Hospital Universitario Vall d'Hebron
      • Barcelona、スペイン、8907
        • Hospital Universitari de Bellvitge (IDIBELL)
      • Barcelona、スペイン、8003
        • Hospital del Mar
      • Girona、スペイン、17007
        • Hospital Universitari de Girona Doctor Josep Trueta
      • Madrid、スペイン、28040
        • Hospital Clínico San Carlos
      • Sabadell、スペイン、8208
        • Parc Taulí Sabadell Hospital Universitari
      • Terrassa、スペイン、8221
        • Universitat de Barcelona - Hospital Universitari Mutua Terrassa (HUMT)
      • Aalborg、デンマーク、9000
        • Aalborg Universitetshospital
      • Aarhus N、デンマーク、8200
        • Aarhus University Hospital
      • Copenhagen、デンマーク、2100
        • Rigshospitalet
      • Herning、デンマーク、7400
        • Herning Regional Hospital
      • Hillerød、デンマーク、3400
        • Nordsjællands Hospital
      • Køge、デンマーク、4600
        • Sjaellands Universitetshospital, Koge - Kardiologisk Afdeling
      • Odense C、デンマーク、5000
        • Odense Universitetshospital
      • Randers、デンマーク、8930
        • Regionshospitalet Randers
      • Slagelse、デンマーク、4200
        • Slagelse Sygehus
      • Viborg、デンマーク、8800
        • Hospitalsenhed Midt
      • Aachen、ドイツ、52074
        • Universitätsklinikum Aachen
      • Hamburg、ドイツ、20246
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Jena、ドイツ、7747
        • University Hospital Jena - Klinik fur Neurologie
      • Leipzig、ドイツ、4103
        • Universitaetsklinikum Leipzig - Klinik und Poliklinik fuer Gastroenterologie und Rheumatologie
      • Münster、ドイツ、48149
        • University Hospital Münster
      • Auckland、ニュージーランド、1023
        • Auckland City Hospital
      • Auckland、ニュージーランド、2025
        • Middlemore Clinical Trials
      • Christchurch、ニュージーランド、8140
        • Christchurch Hospital
      • Dunedin、ニュージーランド、9016
        • Dunedin Hospital
      • Grafton、ニュージーランド、1023
        • Auckland City Hospital
      • Hastings、ニュージーランド、4172
        • Hawke's Bay Hospital Soldiers' Memorial
      • Rotorua、ニュージーランド、3046
        • Lakes District Health Board - Rotorua Hospital
    • WGN
      • Wellington、WGN、ニュージーランド、6021
        • Wellington Hospital
      • Helsinki、フィンランド、290
        • Helsinki University Central Hospital (HUCH)
      • Tampere、フィンランド、33521
        • Tampere University Hospital
      • Turku、フィンランド、20521
        • Turku University Hospital (TYKS)
      • Angers、フランス、49933
        • Centre Hospitalier Universitaire d'Angers
      • Argenteuil、フランス、95107
        • Centre Hospitalier d'Argenteuil
      • Béthune、フランス、62408
        • Centre Hospitalier de Bethune Germon et Gauthier
      • Cergy-Pontoise、フランス、95303
        • Centre Hospitalier René-Dubos
      • Dijon、フランス、21079
        • CHU Dijon - Hôpital François Mitterrand
      • La Roche-sur-Yon、フランス、85000
        • Centre Hospitalier Départemental de Vendée - Les Oudairies
      • Le Kremlin-Bicêtre、フランス、94270
        • Hôpital Bicêtre
      • Le Mans、フランス、72000
        • Centre Hospitalier du Mans
      • Limoges、フランス、87000
        • CHU Limoges - Hôpital Dupuytren
      • Nancy、フランス、54000
        • CHU de Nancy
      • Nantes、フランス、44000
        • CHU de Nantes - Hôtel-Dieu
      • Nîmes、フランス、30029
        • CHU de Nimes - Hopital Universitaire Caremeau
      • Orléans、フランス、45067
        • Hôpital La Source
      • Paris、フランス、75010
        • Hôpital Lariboisière
      • Strasbourg、フランス、67091
        • Hôpitaux Universitaires de Strasbourg - Hôpital Civil
      • Tours、フランス、37044
        • CHRU de Tours - Hôpital Bretonneau
      • Brussels、ベルギー、1020
        • Centre Hospitalier Universitaire Brugmann
      • Charleroi、ベルギー、6042
        • Centre Hospitalier Universitaire (CHU) de Charleroi - Hopital Civil Marie Curie
      • Genk、ベルギー、3600
        • Ziekenhuis Oost-Limburg
      • Ghent、ベルギー、9000
        • Universitair Ziekenhuis Gent
      • Jette、ベルギー、1090
        • Universitair Ziekenhuis Brussel
      • La Louvière、ベルギー、7100
        • Hôpital de JOLIMONT
      • Ottignies、ベルギー、1340
        • Clinique Saint-Pierre- Ottignies
      • Woluwe-Saint-Lambert、ベルギー、1200
        • Cliniques Universitaires Saint-Luc
      • Yvoir、ベルギー、5530
        • CHU UCL Namur - Mont-Godinne
      • Hachioji-Shi、日本、193-0998
        • Tokyo Medical University Hachioji Medical Center
      • Hiroshima、日本
        • Hiroshima University Hospital
      • Izuka-shi、日本、820-8505
        • Aso Iizuka Hospital
      • Izumisano、日本、598-8577
        • Rinku General Medical Center
      • Kashihara-shi、日本、634-8522
        • Nara Medical University Hospital
      • Kumamoto、日本、860-0008
        • National Hospital Organization Kumamoto Medical Center
      • Osaka、日本、534-0021
        • Osaka City General Hospital
      • Osaka、日本、543-0035
        • Osaka Police Hospital
      • Toyoake-Shi、日本、470-1192
        • Fujita Health University Hospital
      • Yokohama、日本、245-8575
        • National Hospital Organization - Yokohama Medical Center
      • Ōmihachiman、日本、523-0082
        • Omihachiman Community Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. 18 years or older.

  2. In the ICU or intermediate care unit for clinical reasons.

  3. Have sepsis requiring vasopressor (norepinephrine, epinephrine, dopamine, phenylephrine, vasopressin, or angiotensin II) therapy, i.e.:

    1. suspected or proven bacterial or viral infection. and
    2. on vasopressor therapy (≥0.1 µg/kg/min norepinephrine or equivalent) for sepsis-induced hypotension for at least one hour despite adequate fluid resuscitation according to clinical judgement. Following the initial one hour on at least 0.1 µg/kg/min norepinephrine or equivalent, any dose of vasopressor counts as vasopressor therapy.

    The combination of a) and b) automatically ensures that patients fulfill the Sepsis 3 criteria as 0.1 µg/kg/min norepinephrine corresponds to a score of +4 on the Cardiovascular sub-score of the SOFA score.

  4. Have AKI according to at least one of the below KDIGO criteria, a to d:

    1. An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours.

      or

    2. A relative increase in CR to ≥1.5 times the pre-AKI reference CR value which is known or presumed to have occurred within prior 7 days.

      or

    3. A decrease in urinary output to <0.5 mL/kg/hour for a minimum of 6 hours following adequate fluid resuscitation.

    or d) If the patient does not have a known history of CKD and there is no pre-AKI reference CR value available from the past 12 months available from the past 12 months: a CR value greater or equal to the levels presented in Table 1, with the increase in CR presumed to have occurred within prior 7 days.

  5. Provision of signed and dated ICF in accordance with local regulations.

Exclusion Criteria:

  1. a) At sites where enrolment of 'moderate' CKD patients is allowed, patients with 'severe' CKD defined as a pre-AKI reference eGFR <25 mL/min/1.73 m2 are excluded.

    • For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥25 mL/min/1.73 m2.

    • For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 25-60 mL/min/1.73 m2 can also be used to rule out 'severe' CKD.

      b) At sites where enrolment of 'moderate' CKD patients is NOT allowed, patients with 'moderate' and 'severe' CKD defined as a pre-AKI reference eGFR <45 mL/min/1.73 m2 are excluded.

    • For patients with known CKD, the most recent eGFR prior to index hospitalization needs to be documented as ≥45 mL/min/1.73 m2.

    • For patients with known CKD but no known eGFR prior to hospitalization, presentation eGFR between 45-60 mL/min/1.73 m2 can also be used to rule out 'moderate' and 'severe' CKD.

  2. Advanced chronic liver disease, defined as a Child-Pugh score of 10 to 15 (Class C).

  3. Acute pancreatitis without proven infection.

  4. Urosepsis related to suspected or proven urinary tract obstruction.

  5. Main cause of AKI not sepsis.

  6. Proven or suspected SARS-CoV-2 infection. NOTE: This exclusion criterion does not apply to patients in the COVID-19 population, in which COVID-19 should be the main cause of SA-AKI.

  7. Severe burns requiring ICU treatment.

  8. Severely immunosuppressed, e.g. due to:

    • hematopoietic cell transplantation within past 6 months prior to Screening or acute or chronic graft-versus-host disease
    • solid organ transplantation
    • leukopenia not related to sepsis, i.e., preceding sepsis
    • Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)
    • receiving chemotherapy within 30 days prior to Screening.
  9. At high risk of being LTFU, e.g., due to known current or recent (within the last 6 months) IV drug abuse or known to be homeless.

  10. Limitations to use of mechanical ventilation (MV), RRT or vasopressors and inotropes (NOTE: limitation of cardiopulmonary resuscitation (CPR) only is not an exclusion criterion).

  11. Previous administration of recAP.

  12. Use of a non-marketed drug within the last month or concurrent or planned participation in a clinical trial for a non-marketed drug or device. (NOTE: Co-enrollment or concurrent participation in observational, non-interventional trials using no protocolized treatments or procedures are always allowed. Co-enrollment or concurrent participation in trials using protocolized treatments or procedures, e.g. blood draws, requires pre-approval by the TSC).

  13. Current or planned extracorporeal membrane oxygenation (ECMO).

  14. On RRT >24 hours before start of trial drug.

  15. No longer on vasopressor therapy at time of randomization.

  16. On continuous vasopressor therapy for >72 hours before start of trial drug.

  17. Estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m2 based on the most recent available CR sample at time of screening (NOTE: will often be the sample used to diagnose AKI). eGFR should be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In Japan, the CKD-EPI formula with Japanese coefficient should be used. If local regulations prohibit correcting for race in the calculation of eGFR, it is acceptable to use the formula without correcting for race.

  18. Not feasible to start trial drug within:

    1. 48 hours from AKI diagnosis, when AKI diagnosis precedes start of vasopressor therapy.

      or

    2. 24 hours from AKI diagnosis, when AKI is diagnosed after start of vasopressor therapy.

  19. Pregnant or nursing women.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:placebo

matching placebo

Placebo

実験的:active

recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions

patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.

他の名前:
  • イロホターゼ アルファ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
28-day All-cause Mortality: Main Trial Population
時間枠:28 days

To demonstrate an effect of recAP on 28 day all cause mortality

28 days
28-day All-cause Mortality: Moderate Chronic Kidney Disease Population
時間枠:28 days

To demonstrate an effect of recAP on 28 day all cause mortality

28 days
28-day All-cause Mortality: COVID-19 Population
時間枠:28 days

To demonstrate an effect of recAP on 28 day all cause mortality

28 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Major Adverse Kidney Events 90: Main Trial Population
時間枠:90 Days

Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level.

90 Days
Major Adverse Kidney Events 90: Moderate Chronic Kidney Disease Population
時間枠:90 Days

Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level.

90 Days
Major Adverse Kidney Events 90: COVID-19 Population
時間枠:90 Days

Major adverse kidney events (MAKE) 90: dead by Day 90 or on Renal Replacement Therapy (RRT) at Day 90 or greater than or equal to 25% decline in estimated glomerular filtration rate (eGFR) on both Day 28 and Day 90 relative to the known or assumed pre-acute kidney injury reference level.

90 Days
Major Adverse Kidney Events Through Day 90: Combined Population
時間枠:90 Days

Major Adverse Kidney Events through day 90 (MAKE90A) :

  • death until day 90
  • greater than 25% drop in estimated glomerular filtration rate at Day 90
  • on renal replacement therapy (RRT) at day 90 OR on RRT through Day 28
90 Days
Days Alive and Free of Organ Support Through Day 28: Main Trial Population
時間枠:28 days

Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days)

28 days
Days Alive and Free of Organ Support Through Day 28: Moderate Chronic Kidney Disease Population
時間枠:28 days

Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days)

28 days
Days Alive and Free of Organ Support Through Day 28: COVID-19 Population
時間枠:28 days

Days alive and free of organ support through Day 28, ie, days alive with no mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors, or inotropes (with death within 28 days counting as zero days)

28 days
Days Alive and Out of the ICU Through Day 28: Main Trial Population
時間枠:28 days

Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

28 days
Days Alive and Out of the ICU Through Day 28: Moderate Chronic Kidney Disease Population
時間枠:28 days

Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

28 days
Days Alive and Out of the ICU Through Day 28: COVID-19 Population
時間枠:28 days

Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

28 days
90-day All Cause Mortality: Main Trial Population
時間枠:90 days

90-Day all-cause mortality

90 days
90-day All Cause Mortality: Moderate Chronic Kidney Disease Population
時間枠:90 days

90-Day all-cause mortality

90 days
90-day All Cause Mortality: COVID-19 Population
時間枠:90 days

90-Day all-cause mortality

90 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:A Legters、AM-Pharma

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年11月2日

一次修了 (実際)

2022年8月18日

研究の完了 (実際)

2022年8月18日

試験登録日

最初に提出

2020年5月28日

QC基準を満たした最初の提出物

2020年5月28日

最初の投稿 (実際)

2020年6月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年10月26日

最終確認日

2024年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • AP-recAP-AKI-03-01

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。